Finerenone + Empagliflozin Offers Greater Benefit in CKD, T2DM
By Elana Gotkine HealthDay Reporter
MONDAY, June 9, 2025 -- For patients with chronic kidney disease and type 2 diabetes, combination finerenone plus empagliflozin leads to a greater reduction in the urinary albumin-to-creatinine ratio than either agent alone, according to a study published online June 5 in the New England Journal of Medicine to coincide with the annual congress of the European Renal Association, held from June 4 to 7 in Vienna.
Rajiv Agarwal, M.D., from the Richard L. Roudebush VA Medical Center in Indianapolis, and colleagues randomly assigned participants with chronic kidney disease (estimated glomerular filtration rate, 30 to 90 mL per minute per 1.73 m2 of body-surface area), albuminuria, and type 2 diabetes, who were taking a renin-angiotensin system inhibitor, to receive finerenone at a dose of 10 or 20 mg per day (with empagliflozin-matching placebo), empagliflozin at a dose of 10 mg per day (with finerenone-matching placebo), or a combination of finerenone and empagliflozin (258, 261, and 265 patients, respectively).
The baseline median urinary albumin-to-creatinine ratio was 579 and was similar among the three groups. The researchers found that at day 180, the reduction in the urinary albumin-to-creatinine ratio with combination therapy was 29 and 32 percent greater than with finerenone alone and empagliflozin alone, respectively (least-squares mean ratio of the difference in the change from baseline, 0.71 and 0.68, respectively). Neither agent led to unexpected adverse events, alone or in combination. Symptomatic hypotension, acute kidney injury, and hyperkalemia rarely led to drug discontinuation.
“The CONFIDENCE study delivers the clear message that simultaneous initiation of finerenone and empagliflozin led to an early and additive reduction in urinary albumin-to-creatinine ratio of 52 percent in patients with chronic kidney disease and type 2 diabetes, which was significantly greater than with either treatment alone,” Agarwal said in a statement. “Since urinary albumin-to-creatinine ratio is a key mediator of kidney and cardiovascular outcomes, these results are highly relevant for clinical decision-making.”
Several authors disclosed ties to Bayer, which manufactures finerenone and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
TUESDAY, July 22, 2025 -- For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke...
ENDO: Guidelines Developed for Pregnancy Care in Preexisting Diabetes
FRIDAY, July 18, 2025 -- In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for pregnancy...
ENDO: Older Age, Female Sex Tied to Greater Muscle Loss With Semaglutide
THURSDAY, July 17, 2025 -- Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.